Polyrizon Ltd. announced encouraging preclinical results from a recent study evaluating its proprietary hydrogel-based Trap & Target (T&T) platform. The study, conducted in collaboration with the University of Parma, demonstrated successful targeted deposition in the upper regions of the nasal cavity.
This targeted delivery is critical for central nervous system (CNS) drug delivery, as these regions are most favorable for nose-to-brain transport. The Polyrizon hydrogel formulation showed a preferential accumulation of over 60% in the middle and upper turbinates, which is crucial for rapid brain access.
Tomer Izraeli, CEO at Polyrizon, stated that these results validate the unique capabilities of the T&T technology in achieving localized deposition in anatomically favorable zones. This opens a strategic path forward for leveraging the intranasal platform in developing therapies for acute neurological and psychiatric conditions, such as opioid overdose and epileptic seizures.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.